COVID‐19 clinical trials: Ethical and scientific consequences of the RECOVERY trial results

The COVID‐19 pandemic has spurred tremendous activity in clinical drug investigations worldwide. One large trial that may influence other trials is the RECOVERY trial, an open‐label, adaptive, multi‐arm, randomized clinical trial (RCT) assessing experimental medicines versus standard of care (SOC) i...

Full description

Saved in:
Bibliographic Details
Published in:Basic & Clinical Pharmacology & Toxicology 2020-12, Vol.127 (6), p.445-447
Main Authors: Dal‐Ré, Rafael, Porcher, Raphaël, Gluud, Christian
Format: Article
Language:English
Subjects:
Clinical Protocols - standards
Clinical trials
COVID-19
COVID-19 - drug therapy
COVID-19 - epidemiology
ethics
Humans
Pandemics
randomized controlled trials
Randomized Controlled Trials as Topic - methods
Randomized Controlled Trials as Topic - standards
RECOVERY
Research Design
results
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The COVID‐19 pandemic has spurred tremendous activity in clinical drug investigations worldwide. One large trial that may influence other trials is the RECOVERY trial, an open‐label, adaptive, multi‐arm, randomized clinical trial (RCT) assessing experimental medicines versus standard of care (SOC) in COVID‐19 hospitalized patients, and with mortality as principal endpoint. Preliminary RECOVERY trial results have shown that dexamethasone reduced death rate in certain patients’ subgroups (positive results), whereas both hydroxychloroquine and lopinavir/ritonavir produced no benefit (negative results) versus SOC.
ISSN:1742-7835
1742-7843
DOI:10.1111/bcpt.13489